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Introduction and Aims: A proliferation-inducing ligand (APRIL) is a critical mediator
for antibody-producing plasma cell survival. Although recent clinical and basic studies
suggest that APRIL may be involved in the pathogenesis of IgA nephropathy (IgAN),
its role in IgAN remains unclear. Since immunological disorders in mucosal immunity
are recently discussed in the pathogenesis, we examined the clinical impact of mucosal
APRIL expression in IgAN patients and assessed underlying mechanisms.
Methods: In addition to clinical background before and after tonsillectomy, the
expressions of APRIL and its receptors (TACI; transmembrane activator and calcium
modulator cyclophilin ligand interactor, BCMA; B-cell maturation antigen) in the
tonsils from IgAN patients (n=56) and control patients (chronic tonsillitis without
renal diseases, n=12) were evaluated by real-time PCR, immunohistochemistry (IHC)
and flow cytometric analysis (FCM). For IHC and FCM with tonsillar samples of IgAN
and control patients, we used two anti-APRIL antibodies specifically recognizing
APRIL-producing cells and secreted form of APRIL (Stalk-1 and Aprily-2,
respectively) and evaluated correlation between these expression pattern and clinical
phenotypes. We examined the presence and patterns of APRIL genetic variants
mRNAs in tonsillar B cells from IgAN patients and controls. The expression levels of
APRIL in some B cell lines under TLR9 stimulation with CpG-ODN were also
evaluated by real-time PCR.
Results: Tonsillar transcriptional levels of APRIL and its receptors in IgAN patients
were significantly higher than those in control patients (P<0.05). IHC revealed that
Stalk-1+ cells in IgAN patients were detected not only in the epithelial areas but also
germinal centers (GC) much more than those in controls. Percentage of Stalk-1+ GC
(27.4±21.3%) in IgAN patients was significantly higher than that in controls (7.2
±6.81%, P=0.0005), and correlated with amount of proteinuria (P=0.0017) and
treatment responses, such as decrease of proteinuria (P=0.0003). Furthermore,
percentage of Stalk-1+ GC was correlated with the serum levels of IgG-IgA immune
complex (IC) in IgAN patients (P=0.0304), but not the serum levels of
galactose-deficient IgA1 (Gd-IgA1). Furthermore, IHC revealed that majority of
Stalk-1+ cells in the tonsillar GC expressed CD19. FCM showed that the percentage of
Stalk-1+ GC B cells in total tonsillar GC B cells was significantly higher in IgAN
patients than controls (P=0.0314). Interestingly, some IgAN patients showed
co-localization of Stalk-1+ and Aprily-2+ B cells in GC. Genetic analysis with tonsillar
B cells indicates the increase of genetic variants lacking APRIL cleavage sites in IgAN
patients. Furthermore, in vitro experiments further showed that TLR9 stimulation
increased APRIL expression in B cell lines.
Conclusions: APRIL+ GC B cells in tonsils may determine the disease activity of IgAN
patients, presumably via the production of anti-glycan or poly-reactive antibody prior
to IC formation with Gd-IgA1. Genetic variation of APRIL and aberrant TLR9
activation in tonsillar B cells may be involved in underlying mechanisms of the
tonsillar APRIL overexpression in IgAN patients.
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